Breast Cancer Trial, Recruiting NCT07439458 Sponsor: Riga Stradins University Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07439458
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the breast cancer group:

  • People who are premenopausal (still having periods and not yet through menopause)
  • People who have been diagnosed with Stage II or Stage III Triple-Negative Breast Cancer, meaning the cancer tests negative for three specific markers (estrogen receptor, progesterone receptor, and HER2)
  • People who finished surgery, chemotherapy, radiation, and/or immunotherapy between 3 and 9 months before joining the trial
  • People whose heart health has been assessed by a heart specialist (cardiologist) as fit for exercise testing, including having had a heart ultrasound (echocardiogram)

For the healthy comparison group:

  • People who are premenopausal (still having periods and not yet through menopause)
  • People who have never been diagnosed with any type of cancer
  • People whose age, body type, and fitness level are a close match to those in the breast cancer group

Who may not be able to join:

  • People who are currently pregnant
  • People who have an autoimmune condition, such as thyroid disease, inflammatory bowel disease, or eczema
  • People who have a hormonal or metabolic condition, such as metabolic syndrome or diabetes
  • People who have a heart or cardiovascular condition
  • People who have been diagnosed with any other type of cancer
  • People who have a health condition that makes physical activity unsafe or inadvisable, such as asthma, chronic lung disease, a spinal disc problem, or severe iron deficiency anaemia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +37126032249

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Riga Stradins University
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
31 March 2026

Where this trial is recruiting

🇱🇻 Latvia

Primary endpoints

Inhibition of Breast Cancer Cell Proliferation; Changes in Serum Myokine Concentrations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov